gptkbp:instanceOf
|
gptkb:drug
synthetic thyroid hormone
|
gptkbp:ATCCode
|
H03AA01
|
gptkbp:brand
|
gptkb:Levoxyl
gptkb:Eltroxin
gptkb:Euthyrox
gptkb:Synthroid
gptkb:Thyrox
|
gptkbp:CASNumber
|
55-03-8
|
gptkbp:chemicalFormula
|
C15H10I4NNaO4
|
gptkbp:contraindication
|
gptkb:thyrotoxicosis
untreated adrenal insufficiency
|
gptkbp:discoveredBy
|
gptkb:Charles_Robert_Harington
|
gptkbp:discoveredIn
|
1926
|
gptkbp:eliminationHalfLife
|
about 7 days
|
gptkbp:essentialMedicine
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
gptkbp:excretion
|
urine
feces
|
https://www.w3.org/2000/01/rdf-schema#label
|
levothyroxine sodium
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:cholestyramine
iron supplements
calcium supplements
antacids
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
increases metabolic rate
binds to thyroid hormone receptors
|
gptkbp:metabolism
|
liver
|
gptkbp:molecularWeight
|
798.86 g/mol
|
gptkbp:pregnancyCategory
|
A (Australia)
|
gptkbp:prescribes
|
gptkb:cancer
gptkb:Hashimoto's_thyroiditis
goiter
congenital hypothyroidism
cretinism
myxedema coma
pituitary TSH suppression
post-thyroidectomy hormone replacement
subclinical hypothyroidism
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
gptkbp:sideEffect
|
anxiety
weight loss
insomnia
palpitations
hyperthyroidism
|
gptkbp:usedFor
|
hypothyroidism
thyroid hormone replacement
thyroid-stimulating hormone suppression
|
gptkbp:bfsParent
|
gptkb:Levoxyl
gptkb:Euthyrox
|
gptkbp:bfsLayer
|
6
|